{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:21:18Z","timestamp":1780327278970,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T00:00:00Z","timestamp":1407801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s12020-014-0377-9","type":"journal-article","created":{"date-parts":[[2014,8,11]],"date-time":"2014-08-11T11:07:58Z","timestamp":1407755278000},"page":"76-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of hyperprolactinemia in post-menopausal women: pros"],"prefix":"10.1007","volume":"48","author":[{"given":"D.","family":"Iacovazzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,12]]},"reference":[{"issue":"1","key":"377_CR1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ecl.2007.10.013","volume":"37","author":"T Mancini","year":"2008","unstructured":"T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. North Am. 37(1), 67\u201399 (2008)","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"8","key":"377_CR2","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1210\/jc.2009-0177","volume":"94","author":"M Kars","year":"2009","unstructured":"M. Kars, P.C. Souverein, R.M. Herings et al., Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J. Clin. Endocrinol. Metab. 94(8), 2729\u20132734 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"377_CR3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0303-7207(82)90084-3","volume":"25","author":"ME Lieberman","year":"1982","unstructured":"M.E. Lieberman, R.A. Maurer, P. Claude, J. Gorski, Prolactin synthesis in primary cultures of pituitary cells: regulation by estradiol. Mol. Cell. Endocrinol. 25(3), 277\u2013294 (1982)","journal-title":"Mol. Cell. Endocrinol."},{"issue":"3","key":"377_CR4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","volume":"54","author":"S Karunakaran","year":"2001","unstructured":"S. Karunakaran, R.C. Page, J.A. Wass, The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin. Endocrinol. 54(3), 295\u2013300 (2001)","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"377_CR5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11102-010-0290-z","volume":"14","author":"V Dos Santos Nunes","year":"2011","unstructured":"V. Dos Santos Nunes, R. El Dib, C.L. Boguszewski, C.R. Nogueira, Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 14(3), 259\u2013265 (2011)","journal-title":"Pituitary"},{"issue":"5","key":"377_CR6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrendo.2011.33","volume":"7","author":"ME Molitch","year":"2011","unstructured":"M.E. Molitch, Pituitary tumors: cabergoline versus bromocriptine: a meta-analysis? Nat. Rev. Endocrinol. 7(5), 254\u2013255 (2011)","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"377_CR7","first-page":"2247","volume":"85","author":"A Colao","year":"2000","unstructured":"A. Colao, A. Di Sarno, M.L. Landi et al., Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J. Clin. Endocrinol. Metab. 85(6), 2247\u20132252 (2000)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"377_CR8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"F.F. Casanueva, M.E. Molitch, J.A. Schlechte et al., Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65(2), 265\u2013273 (2006)","journal-title":"Clin. Endocrinol."},{"issue":"2","key":"377_CR9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"S. Melmed, F.F. Casanueva, A.R. Hoffman et al., Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(2), 273\u2013288 (2011)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"377_CR10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-12-0236","volume":"167","author":"L Vroonen","year":"2012","unstructured":"L. Vroonen, M.L. Jaffrain-Rea, P. Petrossians et al., Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur. J. Endocrinol. 167(5), 651\u2013662 (2012)","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"377_CR11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-13-0503","volume":"170","author":"E Delgrange","year":"2014","unstructured":"E. Delgrange, G. Raverot, M. Bex et al., Giant prolactinomas in women. Eur. J. Endocrinol. 170(1), 31\u201338 (2014)","journal-title":"Eur. J. Endocrinol."},{"key":"377_CR12","doi-asserted-by":"crossref","unstructured":"I. Shimon, M.D. Bronstein, J. Shapiro, G. Tsvetov, C. Benbassat, A. Barkan, Women with prolactinomas presented at the postmenopausal period. Endocrine. (2014). doi: 10.1007\/s12020-014-0259-1","DOI":"10.1007\/s12020-014-0259-1"},{"issue":"4","key":"377_CR13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11102-011-0293-4","volume":"14","author":"G Mazziotti","year":"2011","unstructured":"G. Mazziotti, T. Mancini, M. Mormando et al., High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14(4), 299\u2013306 (2011)","journal-title":"Pituitary"},{"issue":"4","key":"377_CR14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/jcb.22161","volume":"107","author":"D Seriwatanachai","year":"2009","unstructured":"D. Seriwatanachai, N. Krishnamra, J.P. van Leeuwen, Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization. J. Cell. Biochem. 107(4), 677\u2013685 (2009)","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"377_CR15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.bone.2007.11.008","volume":"42","author":"D Seriwatanachai","year":"2008","unstructured":"D. Seriwatanachai, K. Thongchote, N. Charoenphandhu et al., Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand\/osteoprotegerin ratio. Bone 42(3), 535\u2013546 (2008)","journal-title":"Bone"},{"issue":"9","key":"377_CR16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJM198608283150903","volume":"315","author":"A Klibanski","year":"1986","unstructured":"A. Klibanski, S.L. Greenspan, Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. 315(9), 542\u2013546 (1986)","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"377_CR17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1210\/jcem-64-5-1021","volume":"64","author":"J Schlechte","year":"1987","unstructured":"J. Schlechte, G. el-Khoury, M. Kathol, L. Walkner, Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J. Clin. Endocrinol. Metab. 64(5), 1021\u20131026 (1987)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"377_CR18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12020-011-9462-5","volume":"39","author":"G Mazziotti","year":"2011","unstructured":"G. Mazziotti, T. Porcelli, M. Mormando et al., Vertebral fractures in males with prolactinoma. Endocrine. 39(3), 288\u2013293 (2011)","journal-title":"Endocrine."},{"issue":"2","key":"377_CR19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11102-008-0097-3","volume":"12","author":"A Shibli-Rahhal","year":"2009","unstructured":"A. Shibli-Rahhal, J. Schlechte, The effects of hyperprolactinemia on bone and fat. Pituitary 12(2), 96\u2013104 (2009)","journal-title":"Pituitary"},{"issue":"5","key":"377_CR20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","volume":"48","author":"Y Greenman","year":"1998","unstructured":"Y. Greenman, K. Tordjman, N. Stern, Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin. Endocrinol. 48(5), 547\u2013553 (1998)","journal-title":"Clin. Endocrinol."},{"issue":"4","key":"377_CR21","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1210\/jc.2002-021137","volume":"88","author":"C Ling","year":"2003","unstructured":"C. Ling, L. Svensson, B. Oden et al., Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J. Clin. Endocrinol. Metab. 88(4), 1804\u20131808 (2003)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"377_CR22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1530\/eje.0.1470077","volume":"147","author":"M Doknic","year":"2002","unstructured":"M. Doknic, S. Pekic, M. Zarkovic et al., Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur. J. Endocrinol. 147(1), 77\u201384 (2002)","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"377_CR23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF03345182","volume":"26","author":"A Tuzcu","year":"2003","unstructured":"A. Tuzcu, M. Bahceci, M. Dursun, C. Turgut, S. Bahceci, Insulin sensitivity and hyperprolactinemia. J. Endocrinol. Invest. 26(4), 341\u2013346 (2003)","journal-title":"J. Endocrinol. Invest."},{"issue":"1","key":"377_CR24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12020-012-9857-y","volume":"44","author":"SS Inancli","year":"2013","unstructured":"S.S. Inancli, A. Usluogullari, Y. Ustu et al., Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine 44(1), 193\u2013199 (2013)","journal-title":"Endocrine"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-014-0377-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-014-0377-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-014-0377-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:57:03Z","timestamp":1559440623000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-014-0377-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,12]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["377"],"URL":"https:\/\/doi.org\/10.1007\/s12020-014-0377-9","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,12]]}}}